Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD read more 06/15/21
ALSS Secures $7M Series B Funding To Commercialize Novel Vaccine Delivery System For Poultry Industry read more 05/12/21
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory read more 04/27/21
G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression read more 03/02/21
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression read more 02/12/21
Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares read more 12/18/20
